Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience
- 11 June 2013
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 48 (8) , 969-973
Abstract
Objective. To assess the effect of propranolol treatment on the hepatic venous pressure gradient (HVPG) and the relationship between native HVPG and the effect of propranolol in patients with cirrhosis and portal hypertension in a prospective, observational, single-center study. Material and methods. The HVPG was registered prospectively in 124 consecutive cirrhosis patients with and without treatment with propranolol 80 mg daily. Results. 41% of the patients responded to the treatment with the intended reduction of HVPG to 20%. The HVPG reduction was larger for higher native HVPG values (p < 0.001). There was no significant relation between changes in heart rate and changes in HVPG (p = 0.8). Conclusions. The high fraction of hemodynamic non-responders supports the rationale of measuring the HVPG with and without propranolol treatment to assist the clinical assessment and avoid meaningless and potentially harmful treatment. The positive association between a high native HVPG and propranolol-induced HVPG reduction indicates that pharmacological treatment also benefits patients with advanced portal hypertension.Keywords
This publication has 21 references indexed in Scilit:
- The clinical course of alcoholic cirrhosis: effects of hepatic metabolic capacity, alcohol consumption, and hyponatremia – a historical cohort studyBMC Research Notes, 2012
- Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as guidance for prophylaxis and treatment of bleeding and re-bleeding? Yes!European Journal of Internal Medicine, 2011
- The clinical use of HVPG measurements in chronic liver diseaseNature Reviews Gastroenterology & Hepatology, 2009
- How to Prevent Varices From Bleeding: Shades of Grey—The Case for Nonselective β BlockersGastroenterology, 2007
- Effect of Propranolol on Portal Pressure and Systemic Hemodynamics in Patients with Liver Cirrhosis and Portal Hypertension: A Prospective StudyGut and Liver, 2007
- Evolving Consensus in Portal Hypertension Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertensionJournal of Hepatology, 2005
- Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosisJournal of Hepatology, 2004
- Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosisHepatology, 2002
- A Model to Predict Survival in Patients With End–Stage Liver DiseaseHepatology, 2001
- The Hemodynamic Response to Medical Treatment of Portal Hypertension As A Predictor of Clinical Effectiveness in the Primary Prophylaxis of Variceal Bleeding in CirrhosisHepatology, 2000